Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oncolytic herpes simplex virus type 1-mCherry
- Development stage
- Preclinical
- Lead developer
- Università di Padova
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
oncolytic herpes simplex virus type 1-mCherry (oHSV1-mCherry) is a genetically engineered, neuroattenuated oncolytic herpes simplex virus type 1 (oHSV-1) developed by researchers at the University of Padua. It features a genomic backbone similar to the clinically approved talimogene laherparepvec (T-VEC), with deletions in the γ34.5 and Us12 genes to reduce neurovirulence and enhance tumor selectivity. To further prevent replication in healthy neurons, the virus incorporates microRNA-124 (miR-124) target sequences downstream of the essential viral replication gene UL29. It also expresses the mCherry fluorescent reporter protein to allow tracking of viral infection and spread. oHSV1-mCherry is being investigated preclinically for the treatment of glioblastoma (GBM) and acute myeloid leukemia (AML), including studies evaluating its delivery to the central nervous system via carrier monocytes.
- Other names
- mCherry-oHSV1mCherry-oHSV-1mCherry-oHSV 1oHSV-1-mCherryoHSV1-mCherryoHSV 1-mCherryoHSV1-miR124-mCherryoHSV-1-miR124-mCherryoHSV 1-miR124-mCherryΔγ34.5/ΔUs12/miRNA124/mCherry-oHSV-1
Beyond the preview
Go deeper on oncolytic herpes simplex virus type 1-mCherry.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oncolytic herpes simplex virus type 1-mCherry.